{
  "denotations": [
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 141,
        "end": 145
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 207,
        "end": 211
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 216,
        "end": 222
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 156,
        "end": 160
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 128,
        "end": 135
      }
    },
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 83,
        "end": 125
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 68,
        "end": 77
      }
    },
    {
      "id": "T9",
      "obj": "Disease",
      "span": {
        "begin": 141,
        "end": 160
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 68,
        "end": 125
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "24692733_2",
  "text": "BACKGROUND : This study was the first multicenter phase II study of cetuximab plus folinic acid / 5-fluorouracil / irinotecan ( FOLFIRI ) in KRAS wild-type mCRC as a second-line treatment in Japan including BRAF and PIK3CA genotyping ."
}
